Cargando…
The last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure
Heart failure has a high prevalence in the general population. Morbidity and mortality of heart failure patients remain high, despite improvements in drug therapy, implantable cardioverter-defibrillators and cardiac resynchronisation therapy. New transcatheter implantable devices have been developed...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bohn Stafleu van Loghum
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612866/ https://www.ncbi.nlm.nih.gov/pubmed/28741245 http://dx.doi.org/10.1007/s12471-017-1018-8 |
_version_ | 1783266136944541696 |
---|---|
author | Nijenhuis, V. J. Sanchis, L. van der Heyden, J. A. S. Klein, P. Rensing, B. J. W. M. Latib, A. Maisano, F. ten Berg, J. M. Agostoni, P. Swaans, M. J. |
author_facet | Nijenhuis, V. J. Sanchis, L. van der Heyden, J. A. S. Klein, P. Rensing, B. J. W. M. Latib, A. Maisano, F. ten Berg, J. M. Agostoni, P. Swaans, M. J. |
author_sort | Nijenhuis, V. J. |
collection | PubMed |
description | Heart failure has a high prevalence in the general population. Morbidity and mortality of heart failure patients remain high, despite improvements in drug therapy, implantable cardioverter-defibrillators and cardiac resynchronisation therapy. New transcatheter implantable devices have been developed to improve the treatment of heart failure. There has been a rapid development of minimally invasive or transcatheter devices used in the treatment of heart failure associated with aortic and mitral valve disease and these devices are being incorporated into routine clinical practice at a fast rate. Several other new transcatheter structural heart interventions for chronic heart failure aimed at a variety of pathophysiologic approaches are currently being developed. In this review, we focus on devices used in the treatment of chronic heart failure by means of left ventricular remodelling, left atrial pressure reduction, tricuspid regurgitation reduction and neuromodulation. The clinical evaluations of these devices are early-stage evaluations of initial feasibility and safety studies and additional clinical evidence needs to be gathered in appropriately designed clinical trials. |
format | Online Article Text |
id | pubmed-5612866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Bohn Stafleu van Loghum |
record_format | MEDLINE/PubMed |
spelling | pubmed-56128662017-10-05 The last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure Nijenhuis, V. J. Sanchis, L. van der Heyden, J. A. S. Klein, P. Rensing, B. J. W. M. Latib, A. Maisano, F. ten Berg, J. M. Agostoni, P. Swaans, M. J. Neth Heart J Review Article - Point of View Heart failure has a high prevalence in the general population. Morbidity and mortality of heart failure patients remain high, despite improvements in drug therapy, implantable cardioverter-defibrillators and cardiac resynchronisation therapy. New transcatheter implantable devices have been developed to improve the treatment of heart failure. There has been a rapid development of minimally invasive or transcatheter devices used in the treatment of heart failure associated with aortic and mitral valve disease and these devices are being incorporated into routine clinical practice at a fast rate. Several other new transcatheter structural heart interventions for chronic heart failure aimed at a variety of pathophysiologic approaches are currently being developed. In this review, we focus on devices used in the treatment of chronic heart failure by means of left ventricular remodelling, left atrial pressure reduction, tricuspid regurgitation reduction and neuromodulation. The clinical evaluations of these devices are early-stage evaluations of initial feasibility and safety studies and additional clinical evidence needs to be gathered in appropriately designed clinical trials. Bohn Stafleu van Loghum 2017-07-24 2017-10 /pmc/articles/PMC5612866/ /pubmed/28741245 http://dx.doi.org/10.1007/s12471-017-1018-8 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Article - Point of View Nijenhuis, V. J. Sanchis, L. van der Heyden, J. A. S. Klein, P. Rensing, B. J. W. M. Latib, A. Maisano, F. ten Berg, J. M. Agostoni, P. Swaans, M. J. The last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure |
title | The last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure |
title_full | The last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure |
title_fullStr | The last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure |
title_full_unstemmed | The last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure |
title_short | The last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure |
title_sort | last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure |
topic | Review Article - Point of View |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612866/ https://www.ncbi.nlm.nih.gov/pubmed/28741245 http://dx.doi.org/10.1007/s12471-017-1018-8 |
work_keys_str_mv | AT nijenhuisvj thelastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT sanchisl thelastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT vanderheydenjas thelastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT kleinp thelastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT rensingbjwm thelastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT latiba thelastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT maisanof thelastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT tenbergjm thelastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT agostonip thelastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT swaansmj thelastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT nijenhuisvj lastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT sanchisl lastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT vanderheydenjas lastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT kleinp lastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT rensingbjwm lastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT latiba lastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT maisanof lastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT tenbergjm lastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT agostonip lastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure AT swaansmj lastfrontiertranscatheterdevicesforpercutaneousorminimallyinvasivetreatmentofchronicheartfailure |